Ten-year recurrence rates for breast cancer subtypes in the Netherlands: A large population-based study-Reference-Cited by-同舟云学术

Ten-year recurrence rates for breast cancer subtypes in the Netherlands: A large population-based study

Published:2018-11-28 Issue:2 Volume:144 Page:263-272
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

van Maaren Marissa C.¹²^ORCID,de Munck Linda¹³^ORCID,Strobbe Luc J.A.⁴,Sonke Gabe S.⁵,Westenend Pieter J.⁶,Smidt Marjolein L.⁷,Poortmans Philip M.P.⁸,Siesling Sabine¹²

Affiliation:

1. Department of Research; Netherlands Comprehensive Cancer Organisation; Utrecht the Netherlands

2. Department of Health Technology and Services Research; MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente; Enschede the Netherlands

3. Department of Epidemiology; University of Groningen, University Medical Center Groningen; Groningen the Netherlands

4. Department of Surgical Oncology; Canisius Wilhelmina Hospital; Nijmegen the Netherlands

5. Department of Medical Oncology; Netherlands Cancer Institute; Amsterdam the Netherlands

6. Laboratory of Pathology; Dordrecht the Netherlands

7. Department of Surgical Oncology; Maastricht University Medical Centre; Maastricht the Netherlands

8. Department of Radiation Oncology; Institut Curie; Paris France

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ijc.31914/fullpdf

Reference46 articles.

1. Breast cancer: origins and evolution;Polyak;J Clin Invest,2007

2. Modern classification of breast cancer: should we stick with morphology or convert to molecular profile characteristics;Rakha;Adv Anat Pathol,2011

3. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study;Dowsett;J Clin Oncol,2005

4. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status;Dowsett;Ann Oncol,2006

5. Tamoxifen for early breast cancer: an overview of the randomised trials;Early Breast Cancer Trialists' Collaborative Group;Lancet,1998

Cited by 113 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Perioperative systemic IL‐6 and immune‐adipose‐ metabolism transcription in tumour and tumour adjacent breast cancer;European Journal of Immunology;2024-09

2. Estimated incidence of disruptions to event-free survival from non-metastatic cancers in New South Wales, Australia - a population-wide epidemiological study of linked cancer registry and treatment data;Frontiers in Oncology;2024-08-21

3. Second breast cancer following negative breast MRI: Analysis by interval from surgery and risk factors;PLOS ONE;2024-08-15

4. Impact of neoadjuvant compared to adjuvant chemotherapy on prognosis in patients with hormone-receptor positive / HER2-negative breast cancer: A propensity score matching population-based study;The Breast;2024-08

5. 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7);The Breast;2024-08